Klaus Mendla
Consultant / Advisor at Angelini Ventures SpA
Profile
Klaus Mendla acts as an external business development consultant to Angelini Ventures.
He is a life sciences professional with strong scientific background and proven track record in Pharma business development in the field of Central Nervous System (CNS) diseases.
Prior to joining Angelini, Klaus was Global Head of Business Development & Licensing CNS at Boehringer Ingelheim (BI), with worldwide responsibility for all Pharma partnering activities in the company’s therapeutic area CNS diseases.
In this role, Klaus took the lead on developing and implementing BI’s strategy for partnering in the neurology and neuropsychiatry space.
He and his team successfully concluded numerous research collaboration and licensing agreements with Pharma and Biotech companies, with a total deal value in the multi-billion-Euro range.
Before joining BI’s global business development and licensing organization, Klaus was director of Molecular Biology and Neurodegenerative Diseases Research at BI, where he led drug discovery teams focused on novel treatments for Alzheimer’s disease and other neurodegenerative disorders.
Klaus received his PhD degree in Biochemistry and Pharmacology from the University of Muenster (Germany) and completed a postdoctoral fellowship at the University of Heidelberg on the pathophysiology of lysosomal storage diseases.
Klaus Mendla active positions
Companies | Position | Start |
---|---|---|
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Consultant / Advisor | - |
Former positions of Klaus Mendla
Companies | Position | End |
---|---|---|
Boehringer Ingelheim Italia SpA
Boehringer Ingelheim Italia SpA Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Italia SpA engages in the research and development of pharmaceutical drugs for cardiovascular, respiratory and virological diseases. It operates through the following business divisions: prescription and hospital drugs; products for self-medication and well-being; and veterinary medicine. The company was founded in 1972 and is headquartered in Milan, Italy. | Corporate Officer/Principal | - |
Training of Klaus Mendla
University of Münster | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Finance |
Boehringer Ingelheim Italia SpA
Boehringer Ingelheim Italia SpA Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Italia SpA engages in the research and development of pharmaceutical drugs for cardiovascular, respiratory and virological diseases. It operates through the following business divisions: prescription and hospital drugs; products for self-medication and well-being; and veterinary medicine. The company was founded in 1972 and is headquartered in Milan, Italy. | Health Technology |
- Stock Market
- Insiders
- Klaus Mendla